Halozyme Therapeutics | HALO - Aktuelle Verpflichtungen





Aktuelle Verpflichtungen Veränderung Datum
Acadia Pharmaceuticals USD 361.44M 55.91M 2026-06
Agios Pharmaceuticals USD 70.22M 11.37M 2026-06
Alnylam Pharmaceuticals USD 1.51B 163.04M 2026-06
Amarin USD 164.2M 15.45M 2026-06
Amgen USD 25.5B 547M 2026-06
Baxter International USD 3.59B 102M 2026-06
Cara Therapeutics USD 11.26M 216K 2026-03
Cytokinetics USD 181.43M 17.76M 2026-06
DBV Technologies USD 54.3M 2.5M 2026-06
Eli Lilly USD 47.74B 11.11B 2026-06
Halozyme Therapeutics USD 344.44M 18.77M 2026-06
Intrexon USD 23.02M 38K 2024-06
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
MannKind USD 142.9M 8.34M 2026-06
Minerva Neurosciences USD 2.29M 381K 2025-12
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Pfizer USD 32.65B 1.7B 2026-06
Rigel Pharmaceuticals USD 94.4M 7.76M 2025-09
United Therapeutics USD 607.8M 8.7M 2026-06
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12